Syntopix to research biofilms for Beiersdorf AG

17 January 2011
Syntopix to research biofilms for Beiersdorf AG

Deal signed with international branded consumer goods company

Syntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, is pleased to announce that it has signed a research agreement with Beiersdorf AG ("Beiersdorf"), an international branded consumer goods company with a focus on skin care. Beiersdorf, which owns skin care brands such as NIVEA and La Prairie, will pay Syntopix a research contract fee to establish and validate screening assays to improve topical antimicrobial efficacy.

Antimicrobial efficacy on skin surfaces is influenced by specific restrictions that affect delivery and bioavailability of actives, for example release from the formulation or skin penetration. Under the terms of the agreement Syntopix will develop new lab-based assays to help examine the effective delivery of active ingredients in order to maximize their bioavailability on skin.

Dr Stephen Jones, CEO of Syntopix, says: "I am delighted to be working with Beiersdorf. Syntopix's wider work on skin disorders and oral health has given our team a deep understanding of factors affecting the topical efficacy of antimicrobials. Our assays will facilitate the development of new antimicrobial strategies to address this important challenge."

Dr. Heiner Max, Head of Research Personal Care of Beiersdorf adds: "As one of the world's leading cosmetics companies, which is involved in the development and manufacture of skin care products, Beiersdorf's expertise is closely aligned with that of Syntopix. Together we are in a strong position to work towards developing unique and effective products."